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Systems immunology approaches were employed to
investigate innate and adaptive immune responses
to influenza and pneumococcal vaccines. These
two non-live vaccines show different magnitudes of
transcriptional responses at different time points af-
ter vaccination. Software solutions were developed
to explore correlates of vaccine efficacy measured
as antibody titers at day 28. These enabled a further
dissection of transcriptional responses. Thus, the
innate response, measured within hours in the
peripheral blood, was dominated by an interferon
transcriptional signature after influenza vaccination
and by an inflammation signature after pneumo-
coccal vaccination. Day 7 plasmablast responses
induced by both vaccines was more pronounced
after pneumococcal vaccination. Together, these
results suggest that comparing global immune
responses elicited by different vaccines will be crit-
ical to our understanding of the immunemechanisms
underpinning successful vaccination.
INTRODUCTION
Vaccines represent one of the greatest achievements of medi-
cine because they can elicit specific and durable protective
immune response. Most, if not all, preventive vaccines are
designed to initiate protective humoral immune responses. In
the United States alone, over 70 vaccines are currently licensed
(FDA, 2011). Surprisingly, very little is known about the immuno-
logical mechanisms underpinning the development of the pro-
tective immune responses elicited by these vaccines. Profiling
blood transcript abundance on a systems scale has been suc-
cessfully implemented to investigate disease pathogenesis (Ala-
kulppi et al., 2008; Bennett et al., 2003; Pascual et al., 2010;
Ramilo et al., 2007; Tang et al., 2009) and, more recently,responses to vaccines and adjuvants (Bucasas et al., 2011;
Caskey et al., 2011; Gaucher et al., 2008; Mallory et al., 2010;
Nakaya et al., 2011; Querec et al., 2009). The distinct advantage
of a ‘‘systems approach’’ is that it is unbiased (i.e., it does
not require a priori selection of the parameters that will be
measured but instead encompasses the entire available reper-
toire—the human genome). Other large-scale profiling technol-
ogies, such as multiparameter flow cytometry or multiplex
serum protein assays complete the systems immunology arma-
mentarium, providing unprecedented capabilities to charac-
terize the human immune response (Germain et al., 2011;
Maecker et al., 2012).
The volume of data being generated by such approaches is
also unprecedented. With the robustness and cost effectiveness
of high-throughput profiling platforms improving constantly, the
trend is expected to accelerate in the coming years. The chal-
lenges posed by this sudden overabundance of data are many:
from data storage and management to integration, analysis,
and interpretation (Chaussabel et al., 2009; Germain et al.,
2011). Also crucial is an effective means of communicating and
disseminating this wealth of information, especially for investiga-
tors with limited bioinformatics expertise. Indeed, the usefulness
of large-scale data sets can be extended well beyond the publi-
cation of study results by presenting data in a manner that
promotes insight and supports further knowledge discovery.
Providing seamless access to the primary data underlying the
analysis results should also improve transparency and build con-
fidence in the conclusions of a study.
Here, we investigated two widely used vaccines, both of
which induce protective antibody responses. The trivalent influ-
enza vaccine is composed of three chemically inactivated influ-
enza A and B virus strains (split virus vaccine), whereas the
23-valent pneumococcal vaccine consists of polysaccharide
extracts from the 23 most common disease-causing serotypes
of Pneumococcus pneumoniae. We used high-throughput
profiling technologies to measure perturbations that occur in
the blood at the molecular and cellular levels in vivo. By adopting
a comparative approach, we show that these two vaccines elicit
common, as well as distinct, transcriptional signatures, both
early (innate immunity) and late (adaptive immunity), thatImmunity 38, 831–844, April 18, 2013 ª2013 Elsevier Inc. 831
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Systems Scale Exploration of Responses to Vaccineseventually lead to the development of protective antibody
responses. Interactive versions of the figures presented
throughout this paper provide readers with the opportunity to
access the underlying data presented. Furthermore, a portal is
provided to allow the dynamic investigation of the entirety of
the data generated in the context of this study. Finally, insight
gained through data exploration can be gathered, organized,
and shared via integrated email and social networking
applications.
RESULTS
Influenza and Pneumococcal Vaccines Elicit Changes
in Blood Transcript Abundance
Young, healthy, adult volunteers were recruited and randomly
assigned to three study groups receiving either 2009–2010 sea-
sonal influenza vaccine (Fluzone), 23-valent pneumococcal
vaccine (Pneumovax23), or saline injections. Blood samples
were collected by venipuncture at days 7, 0, 1, 3, 7, 10, 14,
21, and 28 (see Tables S1 and S2 available online). Neutralizing
antibody titers elicited by the different vaccines were determined
at days 0 and 28 and demonstrated seroconversion in the major-
ity of subjects (Tables S3 and S4; Figure S1).
Vaccine responses were assessed through the analysis of
global changes in transcript abundance in whole blood samples.
Whole-genome transcriptional profiles were generated at each
time point from the first cohort of volunteers (n = 6 subjects/
group; 162 samples in total). Specific time points where signifi-
cant differences were found in comparison to baseline for each
group (false discovery rate [FDR] = 0.10) were identified. Of the
3,102 transcripts for which abundance was significantly altered
in response to vaccines, 239 changed by more than 2-fold in
at least one time point. Patterns of transcript abundance across
all samples for this robust set are represented on a heatmap (Fig-
ure 1A). In addition, a circular plot was generated where seg-
ments forming the perimeter correspond to differentially
expressed gene lists (Figure 1B). Differentially expressed gene
lists for each group combining all time points and for each time
point combining all the groups are shown on this graph. The
length of each segment is proportional to the number of genes
constituting the list. It is thus possible to visualize that the num-
ber of responsive genes was the largest for the pneumococcal
vaccine group and the smallest for the saline control group.
Among the different time points, the majority of the changes
were seen at days 1 and 7. Connections between the segments
representing the groups (right) and those representing the time
points (left) indicate how differentially expressed genes for a
given group are distributed across the different time points
and, conversely, how genes for a given time point are distributed
across the different groups. An interactive version of this figure
can be used to explore lists of differentially expres-
sed genes (http://www.interactivefigures.com/dm3/circleChart/
arcCirclePlot). This reveals, for instance, that most of the genes
shown at day 7 and all of the genes at day 10 are induced by
pneumococcal vaccination. It also shows both influenza and
pneumococcal vaccines induce robust responses at day 1
postvaccination. This initial analysis indicates substantial
changes in blood transcript abundance can be detected in
response to these two non-live vaccines.832 Immunity 38, 831–844, April 18, 2013 ª2013 Elsevier Inc.Changes in Transcript Abundance Are Detected at the
Module Level 1 and 7 Days Postvaccination
Wenext sought to gain additional insight about the nature of those
vaccine-elicited responses. A modular repertoire analysis was
performed relying on coordinately expressed gene sets, also
called modules. These modules are constructed via an entirely
data-driven process of recapitulating fluctuations in blood tran-
script abundance measured across a wide range of diseases (as
described previously [Chaussabel et al., 2008]) and detailed in
Supplemental Experimental Procedures. Modules are thoroughly
annotated (http://www.biir.net/public_wikis/module_annotation/
V2_Trial_8_Modules) and constitute a simplified framework
for the analysis of blood transcriptome data.
The first step consisted in determining for each module the
proportion of transcripts for which abundance was significantly
changed in comparison to prevaccine levels. A module
is considered to be ‘‘responsive’’ to vaccination when the pro-
portion of significant transcripts is greater that what could be
expected by chance (FDR = 0.10). Out of 62 modules, 17
and 14 passed this threshold at day 1 in the influenza vaccine
and pneumococcal vaccine groups, respectively (Figure 2A).
Subsequently, changes in transcript abundance were detected
for 3 modules and 1 module at day 7 and 10, respectively,
in the pneumococcal vaccine group and for a single module
at day 7 and day 21 in the influenza vaccine group (Figure 2A).
Thus, these two vaccines show different magnitudes
of transcriptional responses at different time points after
vaccination.
Module-Level Exploration of the Innate Responses
to Pneumococcal and Influenza Vaccines
The day 1 responsive modules were mapped on a grid where
each position corresponds to one of the 62 modules used in
this analysis. A colored spot indicates the proportion of signifi-
cant transcripts for a given module. When transcript abundance
for the module increases over the prevaccination levels, the spot
is red; when transcript abundance decreases, it is blue. This
visualization scheme reveals important qualitative differences
between responses elicited by the influenza and pneumococcal
vaccines (Figure 2B).
These figures can be explored via interactive web supple-
ments (http://www.interactivefigures.com/dm3/vaccine-paper/
figure-2.gsp). ‘‘Drill down’’ functionalities provide users with
access to source gene-level data that are integrated with other
data types (clinical information, multiplex cytokine analysis,
and flow cytometry data). In addition, Wiki media was leveraged
to provide access to extensive functional analysis results for
each module. Finally, stringency level of the analysis can be
changed dynamically to assess the robustness of the changes
measured in response to vaccines. A short video tutorial is avail-
able to demonstrate available functionalities.
Influenza and Pneumococcal Vaccines Elicit Distinct
Innate Immune Responses
Changes in eight modules were common to both vaccines,
including increased modules M4.6 (functionally associated with
inflammation), M6.6 and M6.13 (apoptosis/cell death) and
decreased modules M4.1 andM4.15 (T cells), M4.3 (protein syn-
thesis), M5.11, and M6.9 (no functional annotation).
AB
Figure 1. Blood Transcriptional Profiles
of Vaccinated Subjects
(A) Patterns of changes in transcript abundance
are shown on a heatmap for a robust set of 239
transcripts using an FDR of 0.10 and fold change
>2). For each subject, data are normalized to the
average of the two baseline time points. Red rep-
resents relative increase in abundance, blue rep-
resents relative decrease, and yellow represents
no change.
(B) Listsofgenesdifferentiallyexpressed in response
to each treatment for all time points or at each time
point for all treatments are represented as segments
onacircle. The lengthof thesegments isproportional
to the number of genes in each list. A link between
two segments on this circular plot indicates an
overlap between two gene lists between treatments
(segmentson the right) and timepoints (segmentson
the left).An interactivesupplement isavailable for this
figure that dynamically highlights how shared genes
of one segment are distributed across all other seg-
ments and displays symbols for the corresponding
genes (iFigure 1B: http://www.interactivefigures.
com/dm3/circleChart/arcCirclePlot). It also pro-
vides the user with the ability to dynamically add
a cutoff based on fold-change expression over
baseline and to adjust the aspect of the graph. For
study design, see Figure S2 and Tables S1, S2, and
S5; for comparison of transcriptional profiles across
cohorts, see Figure S3.
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Systems Scale Exploration of Responses to VaccinesNine modules were uniquely responsive to the influenza
vaccine. Of those, four were significantly increased and
five were significantly decreased (Figure 3A; http://www.
interactivefigures.com/dm3/vaccine-paper/figure-3.gsp). Three
of the four increased modules were associated with antiviral
responses (M1.2, M3.4, M5.12, Ingenuity Pathway Analysis
enrichment p values) and includedmany genes coding for proto-
typical interferon (IFN)-inducible antiviral molecules such as
OAS1, OAS2, OASL (M1.2); Guanylate Binding Proteins GBP1,Immunity 38, 831–8GBP2, GBP4, GBP6 (M3.4); and TRIM
family members such as TRIM5, TRIM21,
TRIM25, TRIM38, TRIM56 (M5.12). The
fourth increased module, M4.14, was
associated with myeloid lineage and
monocytes and includes, among others,
genes coding for CD97, CD1D, inter-
leukin-6 (IL-6), LY86, and CSF1R. Mod-
ules that were decreased include M3.6
(natural killer cells and cytotoxicity), M4.7
(cell cycle), and three modules without
definitive functional annotation (M4.8,
M5.8, and M6.15).
Six modules were uniquely responsive
to the pneumococcal vaccine. Of these,
five were modules including genes asso-
ciated with inflammation (Figure 3B):
M3.2 (e.g., CD63, IL-1RN, HMGB2,
TLR4, TLR6, TLR8, as well as bcl-6),
M4.2 (e.g., CR1, MMP9, TLR5), M4.13
(e.g., CD58, IL-8RA, CXCL1, and IL-1b),and M5.1 (e.g., CCR1, SERPINB8, MAPK1) and M5.7. Only
one module, M4.12 (not annotated), was decreased. These
day 1 signatures obtained in the first cohort of subjects were
subsequently validated in two independent cohorts of subjects
(Figure S2). There, normalized expression values of individual
transcripts were averaged for each responsive module.
Average values obtained for cohorts 1, 2, and 3 were signifi-
cantly correlated (Pearson correlation, p < 0.001, n = 5–6 sub-
jects per group, Figure S3). These module-based results44, April 18, 2013 ª2013 Elsevier Inc. 833
Figure 2. Modular Mapping of the Global Changes in Blood Transcript Abundance Elicited by Vaccination
Changes in transcript abundance measured in blood by using whole-genome arrays were mapped against a preconstructed modular analysis framework. The
proportion of transcripts for which abundance was significantly changed in comparison to prevaccination levels was determined for each module. When this
proportion exceeded the false discovery rate (set at 10%), the module was considered to be responsive to treatment.
(A) The number of responsive modules is plotted on a graph at each time point for all three of the treatment groups.
(B) Responsivemodules are mapped on a grid for the two vaccine groups at days 1 and 7. The proportion of significant transcripts for eachmodule is represented
by a spot of color, with red representing increased abundance and blue representing decreased abundance. The position on the grid indicates the round and
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Figure 3. Functional Interpretation of Influ-
enza and Pneumococcal Vaccine Day 1 Sig-
natures
Modules specifically responsive to the influenza
(A) or pneumococcal (B) vaccines were subjected
to pathway analysis. Only the genes within each
module for which transcript abundance was
significantly changed following vaccination were
included in this analysis. Genes with at least one
connection (indicating for instance protein-
protein interaction or regulation) are represented in
this figure. An interactive supplement for this
figure provides access to the entire list of
genes that constitute each module and to




Systems Scale Exploration of Responses to Vaccinesdemonstrate how each vaccine elicits a distinct innate immune
response.
Changes in Blood Transcript Abundance Are Detected
within Hours following Vaccine Administration
To further analyze the kinetics of the innate response to vacci-
nation, we generated whole-genome transcriptional profiles
from blood collected within hours following vaccine or saline
administration in an independent patient cohort (n = 6 subjects
per group). Blood samples were collected via finger stick at
hours –168, 0, 1.5, 3, 6, 9, 12, 15, 24, 36, and 48, for whole-
genome transcriptional profiling (198 samples in total) (see Ta-order of selection. For instance, the fourth module of the third round of selection (M3.4) is situated in the four
spots denotes the percentage of significant transcripts. A legend is provided with functional interpretations in
An interactive supplement is available for this figure that provides access to gene level data and extensive func
figure also allows users to dynamically adjust the stringency of the analysis (iFigure 2B: http://www.interact
Immunity 38, 831–8ble S5). Changes in transcript abun-
dance at each time point postvaccina-
tion were identified as described above.
To characterize the nature of the
evolving innate immune response, we
systematically compared these signa-
tures with gene-expression profiles
induced by in vitro culture of blood with
a wide range of Toll-like receptor (TLR)
agonists and cytokines. The concor-
dance between in vivo and in vitro signa-
tures is shown by using circular plots
(Figure 4; http://www.interactivefigures.
com/dm3/vaccine-paper/figure-4.gsp).
There, the degree of connectivity be-
tween the various segments on the plot
indicates the degree of overlap between
the in vivo- and in vitro-derived gene
lists. The signature elicited within hours
following immunization with seasonal
influenza vaccine overlapped with tran-
scripts induced by a small set of innate
immune stimuli including heat-inacti-vated gram-negative bacteria, heat-inactivated viruses (RSV,
influenza), and IFN-g. The overlapping gene transcript set was
dominated by interferon-inducible genes, including the tran-
scription factor EGR1, ADAR (RNA-editing enzyme that deami-
nates adenosines and modifies viral genomes), Fcg receptors,
GBP1 and GBP2 (IFN-inducible, specifically bind guanine nu-
cleotides), IFI16 (amplifier in intracellular DNA recognition
response), HLX (transcription factor involved in T helper 1 cell
(Th1)-type response polarization), IRF1 and IRF9 (transcription
factors involved in type I IFN production and IFN signaling),
STAT1 (transcription factor that mediates the IFN response),
TAP1 (involved in antigen presentation via MHCI), TLR7th column, third row. The degree of intensity of the
dicated at each position of the grid by a color code.
tional annotations for eachmodule. The interactive
ivefigures.com/dm3/vaccine-paper/figure-2.gsp).
44, April 18, 2013 ª2013 Elsevier Inc. 835
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Systems Scale Exploration of Responses to Vaccines(receptor for single stranded RNA) and TRAIL (TNFSF10,
involved in induction of apoptosis). The pneumococcal vaccine
signature overlapped with in vitro signature induced by heat-in-
activated bacteria, LPS, flagellin, PAM3, R837, zymosan, CpG,
IFN-g, IL-18. The overlapping gene transcript set included
IL-1B, IL-1RN, IL-6R, ADM (a vasodilatator), FCGR2A, TRAIL
and CASP4 (apoptosis inducers), IRF2 (inhibits IRF1-mediated
IFN induction and binds to the IL7 promoter), and transcription
factors BCL3 (NF-kB signaling), VAV1 (Rho signaling), BCL6,
and ETS2 (leukocyte differentiation and/or proliferation). The
gene lists obtained for the control saline group were only
sparsely connected. This analysis demonstrates that vaccines
act as potent activators of the innate immune system and that
responses can be detected in the blood in vivo within hours
following administration. The interactive online figure allows
further exploration of the circular plots, giving readers the ability
to dynamically display lists of overlapping genes and change
the stringency of the filters (Figure 4; http://www.
interactivefigures.com/dm3/vaccine-paper/figure-4.gsp).
A Modular Interferon Signature Is Detected 15 hr
following Influenza Vaccination
To complement observations made at the gene level, we next
analyzed early transcriptional responses to vaccines at the mod-
ule level. Baseline-normalized values for each gene within a
module were averaged. We decided to focus on IFN-inducible
modules and to further investigate the kinetics of induction by
the influenza vaccine (M1.2 shown on Figure 5A and with
each point linked to detailed sample information in http://www.
interactivefigures.com/dm3/vaccine-paper/figure-5.gsp). Sig-
nificant changes in the transcription of genes forming
IFN response module were observed as early as 15 hr follow-
ing administration of the vaccine and persisted to 48 hr
postvaccination.
Next, the contributions were determined for different leuko-
cyte populations to this interferon signature. To this end, we
isolated neutrophils, monocytes, and CD4+ and CD8+ T cells
from the blood of study subjects before and 24 hr after the
administration of the influenza vaccine (n = 6) in a third sequen-
tial cohort of healthy subjects (48 samples in total). The analysis
revealed differences in the levels of expression for IFN-induc-
ible transcripts in neutrophils and in monocytes following influ-
enza vaccination (module-level data shown in Figure 5B; http://
www.interactivefigures.com/dm3/vaccine-paper/figure-5.gsp).
Furthermore, serum levels of the IFN-inducible chemokine
CXCL10 (IP-10) were also found to increase significantly on
day 1 after influenza vaccination (p < 0.01; Figure S4).
Thus, administration of the influenza vaccine leads to early
type I interferon signature in the blood carried by neutrophils
and monocytes.Figure 4. Mapping of the Response to Vaccines In Vivo and the Respo
Lists of genes differentially expressed at nine consecutive time points post vaccine
of innate stimuli are represented as segments of a circle. The lengths of the segm
segments on this circular plot indicates an overlap between two gene lists. The d
degree of overlap between in vivo- and in vitro-derived gene lists. An interactiv
segments are selected. The tension of lines and stringency of the filters (fold ch
p value slider, baseline and time point microarray data were used in paired t tests.
p value filter (iFigure 4: http://www.interactivefigures.com/dm3/vaccine-paper/figPneumococcal Vaccine Elicits a Prominent Plasmablast
Signature on Day 7
Wenext analyzedmodular transcriptional responses at later time
points after vaccine administration. Day 7 samples demon-
strated changes in the abundance of transcripts constituting
module M4.11 in both the influenza and pneumococcal vaccine
groups (Figure 2B). This module includes genes encoding CD38,
IGJ, TNFRSF17 (BCMA), TXNDC5, GLDC, CAMK1G, and immu-
noglobulin kappa chains and constitutes a plasma cell precursor
signature. At day 7, the abundance of 35% of the transcripts
forming module M4.11 increased significantly in comparison to
prevaccination levels in the influenza vaccine group. In the pneu-
mococcal vaccine group, 70% of the M4.11 transcripts were
significantly increased. Furthermore, the amplitude of the
plasma cell precursor signature induced by pneumococcal
vaccination was significantly greater than that induced by influ-
enza vaccination at both days 7 and 10. As described above,
baseline-normalized values for each gene within a module
were averaged and plotted on a graph (Figure 6A; http://www.
interactivefigures.com/dm3/vaccine-paper/figure-6.gsp). These
results were reproduced in our validation cohort (cohort 2, n = 6
subjects per group). Two other modules, M3.3 and M4.9, were
responsive to pneumococcal vaccination only at day 7 (data
not shown). Genes from M3.3 code for molecules involved in
cell cycle and replication, including a number of cyclins, kinesins,
and centromere proteins; functionally, M3.3 is associated with
hematopoiesis. Module M4.9 includes molecules involved in
leukocyte extravasation (ACTG1, CXCR4, CDC42, CRK,
ROCK1, and RASSF5). These findings at the transcriptional level
are in linewith changes in cellular composition showing a spike in
circulating plasmablasts at day 7 after vaccination. Plasmablasts
were identified by polychromatic flow cytometry in whole blood
samples as CD19+/loCD20CD27+CD38hi plasmablasts and
plasma cells. Figure 6B shows the kinetics of changes in the
absolute numbers of CD19+ B cells and plasmablasts over
time after vaccination. There, 11-fold and 47-fold increases in
the absolute numbers of plasmablasts were observed following
vaccination with influenza and pneumococcal vaccines, respec-
tively. The peak levels reached a mean of 8.5 cells/uL and 71.7
cells/uL in response to influenza and pneumococcal vaccines,
respectively. This increase was significant at day 7 following
administration of the influenza vaccine and on days 7 and 10
following administration of the pneumococcal vaccine. The inter-
active figure provides access to the flow cytometry pseudo-
color dot plots that show the composition of the B cell
compartment (Figure 6B; http://www.interactivefigures.com/
dm3/vaccine-paper/figure-6.gsp). Consistent with transcrip-
tional profiles, both vaccines lead to expansion of plasmablasts
and/or plasma cells with a much greater expansion observed
after pneumococcal vaccine (range: 11.4%–35.9% versusnse to Innate Immune Ligands In Vitro
administration or following in vitro treatment of blood for 6 hr with a wide range
ents are proportional to the number of genes in each list. A link between two
egree of connectivity between the various segments on this plot indicates the
e supplement is available for this figure. Overlapping genes are listed when
ange and p value slider) can be adjusted dynamically. For computation of the
For each paired in vitro/in vivo gene, the greater p value of the pair is used in the
ure-4.gsp).
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Systems Scale Exploration of Responses to Vaccines27.9%–86.2%, respectively). Thus, blood transcriptional
profiling and flow cytometry reveal qualitative and quantitative
differences in adaptive immune responses to these two vaccines
with pneumococcal vaccine generating larger and longer lasting
plasmablast responses.
Exploring Correlation Patterns Predictive of Vaccine
Response
Mining of large-scale immune profiling data can yield critical
insight into factors determinant of effective vaccination. We
explored correlations between day 1 and day 7 modular finger-
prints and increases in antibody levels for all available serotypes,
combining results from all available subjects for both vaccination
groups. The strongest correlations were observed between
day 7 modular transcriptional data and serology results in the
pneumococcal vaccine group. The strongest positive correla-
tions were found for modules M3.3 (annotated as cell cycle)
and M4.11 (plasma cells) and to a lesser extent M4.10 (B cells),
M5.10 and M6.2 (both associated with mitochondrial respira-
tion). Strong negative correlations were observed at the same
time point for modules associated with inflammation (M3.2,
M4.2, and M4.13). Showing correlation (r) values in a heatmap
format revealed a high degree of consistency in these correla-
tions across all serotypes (Figure 7A). In contrast, correlation
patterns observed between day 7 modular transcriptional data
and serology results in the influenza vaccine group were more
varied for the different virus strains tested. The vaccine used in
this study (2009/10 Fluzone from Sanofi Pasteur) contained inac-
tivated A/Brisbane/59/2007 IVR-148 (H1N1), A/Uruguay/716/
2007 NYMC X-175C (H3N2) (an A/Brisbane/10/2007 H3N2-like
virus), and B/Brisbane/60/2008 strains. Some day 7 modules
correlating to levels of antibodies were similar to those found in
the pneumococcal vaccine group (M4.11 and M4.10) (Figure 7B)
with B Brisbane showing the strongest positive correlation with
M4.11 and an increase in HAI titers (r = 0.77). Levels of antibodies
against the Brisbane H3N2 strain were inversely correlated with
M3.3 (cell cycle) in contrast to a positive correlation for B Bris-
bane and Brisbane H1N1 strains. Correlation patterns
were also observed in day 1 influenza vaccine modular signa-
tures, which showed positive correlations of IFN modules
M1.2, 3.4, and M5.12 (http://www.interactivefigures.com/dm3/
vaccine-paper/figure-7.gsp). Although independent validation of
these findings will be required, these results highlight the value
of using unbiased exploratory approaches toward identification
of determinants of successful vaccine responses.
DISCUSSION
We demonstrate that different vaccines against infectious
agents elicit different transcriptional and cellular responses inFigure 5. Profiling the Interferon Response within the First 48 hr follow
(A) Baseline-normalizedwhole-blood expression levels of genes formingmoduleM
are shown at multiple consecutive time points for the influenza vaccine and salin
CXCL10 (IP-10), see Figure S4.
(B) Baseline-normalized expression levels of genes forming module M1.2 were av
isolated from the blood of subjects 24 hr postvaccination. Box plots with whiskers
for this figure, where detailed sample information is accessible seamlessly for ea
vaccine-paper/figure-5.gsp).the blood. Indeed, both seasonal influenza and pneumococcal
vaccines showed a spike in transcriptional activity within 24 hr af-
ter intramuscular administration, suggesting activation of the
innate immune system. However, there were important qualita-
tive differences in the transcriptional profiles. Whereas the
pneumococcal vaccine induced an increase in abundance of
myeloid- and inflammation-related gene transcripts, the influ-
enza vaccine produced an IFN-inducible transcriptional signa-
ture at day 1 after vaccination. Neither vaccine includes an
adjuvant, but they differ fundamentally in their composition. The
seasonal influenza vaccine is composed of inactivated virus par-
ticles, whereas the pneumococcal vaccine is composed of a mix
of polysaccharides. Thus, different vaccines might lead to devel-
opment of adaptive immunity through different innate immune
pathways. However, a mechanism common to both vaccines is
also at play as demonstrated by the shared transcriptional pro-
files at day 1 that we observed for 8 modules, including upregu-
lation of modules related to myeloid lineage and inflammation.
To investigate the kinetics of the early innate vaccine
response, we collected blood by a finger prick and by using tran-
scriptional profiling detected the upregulation of IFN-inducible
genes as early as 15 hr after vaccine administration. In
line with our observations, Bucasas et al. reported for the
2008–2009 seasonal influenza vaccine upregulated expression
of interferon signaling genes like STAT1 and IRF9 in the blood
on day 1 after vaccination (Bucasas et al., 2011). Although the
study by Nakaya et al. did not include collection of blood sam-
ples on day 1 after vaccination, this group reported on a signa-
ture of IFN-related genes in purified blood mononuclear cells
(rather thanwhole blood) on day 3, thus correlating with the sero-
logical response to vaccination with inactivated influenza vac-
cine (Nakaya et al., 2011).
We went further and isolated neutrophils, monocytes, and
CD4+ and CD8+ T lymphocytes from peripheral blood before
and 1 day after vaccination. This analysis revealed that neutro-
phils and monocytes are the main cellular source of the day 1
influenza vaccine interferon signature in the blood. Interestingly,
we have recently identified a similar neutrophil- and monocyte-
driven blood interferon signature correlating with disease
severity in patients with tuberculosis (Berry et al., 2010).
At day 7 after vaccination, we found plasmablast-related gene
transcriptional activity consistent with a generation of adaptive
immune responses, confirmed by detection of humoral immune
responses at day 28 (as shown by serology). Transcripts include
genes such as CD38 or TNFRSF17 (BCMA), one of the receptors
of BlyS-BAFF, which have previously been described as part of a
day 7 peripheral blood mononuclear cell (PBMC) signature pre-
dictive of the neutralizing antibody response to yellow fever
vaccination and (inactivated) seasonal influenza vaccine
(Nakaya et al., 2011; Querec et al., 2009). A burst in circulatinging Vaccination
1.2 (IFN-inducible genemodule) were averaged and plotted on a graph. Values
e control groups. For concomitant serum increase of IFN-inducible chemokine
eraged and plotted on a graph. Values are shown for different cell populations
indicatingminimum andmaximum value. An interactive supplement is available
ch data point on the graph (iFigure 5: http://www.interactivefigures.com/dm3/
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Figure 6. Plasma Cell Precursor Immune Signature
(A) Baseline-normalized whole blood expression levels of genes forming module M4.11 (plasma cell precursors module) were averaged and plotted on a graph.
Values are shown at multiple consecutive time points for the influenza vaccine, pneumococcal vaccine and saline control groups.
(B) Abundance of plasmablasts measured by multi-parameter flow cytometry is plotted on a graph. Values are shown at multiple consecutive time points for the
influenza vaccine, pneumococcal vaccine and saline control groups. Box plots with whiskers indicatingminimum andmaximum value. An interactive supplement
is available for this figure where detailed sample information including dot plots for flow cytometry measurements is seamlessly accessible for each data point on
the graph (iFigure 6: http://www.interactivefigures.com/dm3/vaccine-paper/figure-6.gsp).
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Systems Scale Exploration of Responses to Vaccinesplasmablasts was concomitantly observed at day 7 by flow
cytometry. This is consistent with recent studies by Nakaya
et al. (2011) and Querec et al. (2009) and suggests the develop-
ment of adaptive immune responses. Indeed, Wrammert et al.
showed that up to 85% of plasmablasts purified at the peak of
response can be influenza-vaccine-specific, pauciclonal, and
producing mainly immunoglobulin G (IgG) of highest affinity
(Wrammert et al., 2008).
Two studies recently reported a correlation between day 1 or
day 3 upregulated genes involved in IFN signaling and the
magnitude of the antibody response (Bucasas et al., 2011;
Nakaya et al., 2011). Exploratory analysis of correlation patterns
in the influenza vaccine group showed a correlation of day 1
moduleM5.12 (IFN) expression and serological response to Bris-
bane H1N1 (r = 0.66) and of day 7M4.11 (plasma cells) with sero-
logical response to B Brisbane vaccine strain (r = 0.77). Likewise,
day 7 module M4.11, as well as M4.10 (B cells), correlated with
serological response. Together, these results suggest that
comparing global immune responses elicited by different vac-
cines will be critical to our understanding of the immune mecha-
nisms underpinning successful vaccination.
An important goal of this work was to implement means to
extend the value of data generated by using systems immu-
nology approaches beyond publication of the results. Therefore,
we developed web applications to allow mining and interpreta-
tion of the data by other investigators. In addition to interactive
figures, we developed a data portal allowing users to dynami-
cally query and graph the primary data generated in this
study (http://www.interactivefigures.com/dm3/vaccine-paper/
portal-landing.gsp). There, profiles of individual genes can be
plotted and integrated with any clinical or immunological data
with a user-friendly data browsing application (http://www.
interactivefigures.com/dm3/flash/vaccine-paper-dataportal/
iFig_dataportal.html). We have also integrated features that
facilitate the harvesting and dissemination of findings that inves-
tigators discover while browsing the data. All images and under-
lying data are downloadable and web links that record a specific
view of the data can be shared by email directly from the appli-
cation. We also leveraged social networking media to facilitate
sharing of these findings (http://www.interactivefigures.com/
dm3/flash/vaccine-paper-gplusfig/gPlusFig.html). Registered
Google+ users can, at the click of a button, post web links and
images from our application, along with personal notes to prede-
fined ‘‘circles.’’ Google+ circles consist of other users and can be
private, supporting a personal collection of notes, or include a
selection of followers who will receive notifications when a new
‘‘discovery note’’ is posted.
Thus, this work explores a new paradigm for the publication of
results from systems studies. The vast amounts of data gener-
ated when profiling immune response on a large scale often
remain ‘‘hidden’’ behind the main results presented in a manu-
script. Furthermore, when primary data is deposited in public re-
positories, it is often incomplete and is not readily accessible to
investigators with limited bioinformatics expertise. Here, state-
of-the-art application development was leveraged to provide
readers with the opportunity to interact with the data underpin-
ning each figure. We employed Web 2.0 concepts to build appli-
cations that support dynamically updated page content and the
performance of computationally intensive tasks on a remoteserver (in this instance, on a cloud server) without the need for
downloading or installing new software. Making data available
via such web applications improves the transparency of the
results. In addition, bridging the gap between investigators pos-
sessing vast immunological expertise and the large amounts of
data generated in the context of systems profiling studies will
promote further insights and knowledge discovery.
EXPERIMENTAL PROCEDURES
Study Subjects and Study Design
The study was approved by the Baylor Research Institute Institutional Review
Board at Baylor University Medical Center (Dallas, TX). After obtaining written
informed consent, healthy adults, aged 18 to 64 years, were enrolled to receive
a single intramuscular dose of 2009–2010 seasonal influenza (Fluzone, Sanofi
Pasteur, PA), pneumococcal vaccine (Pneumovax23, Merck, NJ), or placebo
(saline). Exclusion criteria were pregnancy, active allergy symptoms, or vacci-
nations within the previous 2months. Prior to vaccination, participants had two
baseline blood draws (on days 7 and 0, with respect to the day of vaccina-
tion; see Tables S1 and S2 for study design). Blood was collected in Tempus
blood RNA tubes (Life Technologies) for microarray and acid citrate dextrose
tubes (ACD, BD Vacutainer) for whole-blood flow cytometry, CBC, and serum
analysis of neutralizing antibodies (Figure S1) and cytokines (Figure S4). In
addition, capillary blood was collected by finger stick for microarray (see Table
S5 for study design). Freshly ficolled PBMC were used for sequential isolation
of white blood cell subsets (see below).
Microarray Assay
Total RNA was isolated from the whole-blood lysate (Ovcharenko et al., 2005)
followed by depletion of globin messenger RNA (Whitley et al., 2005). All sam-
ples passing quality control were then amplified and labeled by using the Illu-
mina TotalPrep-96 RNA amplification kit. Amplified RNA was hybridized to
Illumina HT-12 V3 beadchips (48,803 probes) and scanned on an Illumina
Beadstation 500. Illumina’s BeadStudio version 2 software was used to
generate signal-intensity values from the scans. After background subtraction,
the average normalization recommended by the BeadStudio 2.0 software (Illu-
mina, San Diego, CA) was used to rescale the difference in overall intensity to
the median average intensity for all samples across multiple arrays and chips.
For modular analysis, a set of 260 transcriptional modules was used as a pre-
existing framework for the analysis of this data set. The approach used for the
construction of such framework was previously reported (Chaussabel et al.,
2008). Briefly, genes with coordinate expression within or across nine
whole-blood disease data sets where selected in multiple rounds of clique
and paraclique clustering to form a 260 transcriptional module framework
(see also Supplemental Experimental Procedures). Following the transforma-
tion of gene level data into module level activity scores, both unsupervised
and supervised analyses of the complete data set were conducted.
Flow Cytometry
We incubated 200 uL of whole blood with pretitrated monoclonal antibodies
for 15 min at room temperature followed by lysis of red blood cells
(BD FACS Lyse). Samples were processed within 2 hr after blood draw and
acquired on a BD Special Order LSRII flow cytometer. Analysis was performed
by using FlowJo software (version 8.8.6, TreeStar, Inc.).
Isolation of WBC Subsets
Neutrophils were first separated from mononuclear cells by Ficoll gradient
centrifugation, followed by hypotonic lysis of red blood cells in KHCO3 and
NH4Cl and finally purified by negative selection by using the EasySep Human
Neutrophil Enrichment Kit (Stemcell); monocytes (CD14+) and T lymphocytes
positive for the CD4 and CD8 antigen were sequentially isolated from PBMC
by using Dynabeads (Invitrogen) according to the manufacturer’s instructions.
In Vitro Stimulation with Innate Immune Ligands
Fresh whole blood of four healthy subjects was incubated for 6 hr at 37C with
18 different stimuli or left unstimulated and followed by RNA stabilization with
Tempus reagent and sample storage at 20C until RNA extraction, asImmunity 38, 831–844, April 18, 2013 ª2013 Elsevier Inc. 841
Figure 7. Correlation Patterns of Day 7 Transcriptional Data and Antibody Titers
Correlations between day 7 baseline-normalized averaged modular expression profiles and fold change of day 28 antibody titer over baseline for all available
pneumococcal serotypes and influenza vaccine strains are represented on a heatmap. Modules are shown in rows and serotypes in columns. Red indicates
(legend continued on next page)
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E-LPS, Flagellin, R837, CpG Type A, heat-killed Legionella pneumophila
(HKLP), heat-killed Acholeplasma laidlawii (HKAL), and heat-killed Staphylo-
coccus aureus (HKSA) (all from Invivogen); IL-18, TNF-a, IFN-a2b, IFN-b,
IFN-g (all from Peprotech); heat-killed Escherichia coli (in house preparation),
live influenza A virus and live respiratory syncytial virus (RSV).
Hemagglutinin Inhibition and Virus-Neutralization Assays for
Quantitating Seasonal Influenza Virus Neutralizing Antibodies
Briefly, 2-fold serial dilutions of human sera were mixed and preincubated in
96-well plates for 30 min at room temperature with 8 hemagglutinin units of
virus (H1N1 A/Brisbane/59/2007 and H3N2 A/Brisbane/10/2007) per well.
Turkey red blood cells were used for detection of neutralizing antibodies
against H3N2 A/Brisbane/10/2007, whereas chicken red blood cells were
used or detection of neutralizing antibodies against H1N1 A/Brisbane/59/
2007. Red blood cells were added at a final concentration of 0.25% per well,
and the plate was incubated at room temperature for 30 min. Neutralizing anti-
body titers were determined as the reciprocal value of the highest dilution that
displayed no hemagglutinating activity. Virus-neutralization assays were per-
formed by using the same virus strains and as reported earlier (Steel et al.,
2009). Antibody response to 14 pneumococcal polysaccharides was
measured by using commercial immunoassays.
Multiplex Cytokine Analysis
Sera were analyzed for cytokine production by using the Multiplex 42-human
cytokine and chemokine panel of antibodies conjugated beads and biotin pairs
(Cf. Luminex Technology, Millipore) according to the manufacturer’s instruc-
tions and run on Bio-Plex 200 and Bio-Plex 100 readers (Bio-Rad
Laboratories).
Statistical Methods
Background-subtracted microarray data were obtained from Illumina’s
GenomeStudio software. Expression values less than 10 were set to 10, log
(base 2) transformed, and quantile normalized. For flow data processing, all
continuous outcome variables were log (base 2) transformed to better meet
the normality assumption of the linear mixed model (LMM) analyses. Both
microarray- and flow cytometry-derived variables were analyzed by using
LMMs, which included time as a categorical variable with a first-order autore-
gressive residual covariance matrix. Specific contrasts were used to test for
differences between postvaccination and both prevaccination time points.
When applicable, differences between the two prevaccination time points
were also tested as a control. A FDR of 0.10 was used to adjust for multiple
testing (Benjamini and Hochberg, 1995). For each vaccine study in cohort 1,
microarray probes were modeled individually. The number and proportion of
differentially expressed probes (both up and downregulated) was determined
per module and time point comparison. Modules containing a proportion of
probes greater than an FDR of 0.10 were considered active at the specified
time point and further investigated. The results in cohort 1 were validated in
subsequent cohorts. The mean of all probes within a module was calculated
for each observation and analyzed by using the same LMM as previously
described. Statistical analyses of microarray, Luminex, flow cytometry, and
serology data were performed by using SAS software (v9.2), JMP (v8), and
JMP/Genomics (v4.0) (each from SAS Institute, NC).
Generation of Circular Plots
The in vivo vaccine response data sets were processed as described above.
The in vitro stimulation data set was preprocessed by using quantile normal-
ization and flooring all values to 10. Probes that did not have a detection
p value < 0.01 in at least 10% of all samples across all stimuli and donors
were excluded. For each stimulation, probes were identified with a fold
change of greater than 2 or less than 0.5, when compared to the respectivestrong positive correlation, and blue indicates strong negative correlation. (A) sho
change [FC] in virus neutralization [VN] and hemagglutinin [HAI] titers). An interac
modules and select additional parameters for correlation (iFigure 7: http://ww
associated p values were calculated via the Spearman method and can be a
controlled by an on/off toggle. For details on serological response, see also Figunonstimulated donors. Probes were identified separately for each stimulation
and had absolute value difference >100 when compared to the nonstimulated
donors. Finally, for each stimulation, probes were identified for which at least
3 samples passed both the fold change and signal difference threshold
cutoff.
ACCESSION NUMBERS
Data have been deposited in the NCBI Gene Expression Omnibus under code
GSE30101.
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